"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

Like benign MS, RRMS can change its course. When RRMS transitions into progressive MS, it’s called secondary progressive MS (SPMS). There are no clear periods of remission in SPMS. People with ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

The following is a summary of “Neurofilament heavy chain in secondary progressive multiple sclerosis,” published in the January 2025 issue of Neurology by Angelis et al. Biomarkers are essential for ...

most people have relapsing-remitting MS. Other types include primary progressive MS, secondary progressive MS, and clinically isolated MS. Contact your doctor if you have concerns about MS. They ...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this form of the ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

“We are excited to announce this breakthrough in understanding how nasal foralumab induces immune modulation in Secondary Progressive MS patients,” said Dr. Tanuja Chitnis, M.D., Principal ...

Tiziana Life Science announced its intention not to engage in a capital raising activities for the immediate future. Following on from its news ...